Synagis Re-Treatment Patients Represent 21% Of Use, MedImmune Says
Re-treatment with Synagis made up approximately 21% of MedImmune's sales of the monoclonal antibody product during last year's respiratory syncytial virus season.
Re-treatment with Synagis made up approximately 21% of MedImmune's sales of the monoclonal antibody product during last year's respiratory syncytial virus season.